Cointime

Alnylam Pharmaceuticals

company

About

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.

  • 1001 - 5000

Highlights

Total Funding Amount
$834.60M
Funding Rounds
3
Investors
4

Details

Last Funding Type
Private Equity（PE）
Last Funding Money Raised
$24.60M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2002
Number Of Employee
1001 - 5000
Operating Status
Active

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$834.60M
Alnylam Pharmaceuticals has raised a total of $834.60M in funding over 2 rounds. Their latest funding was raised on Apr 8, 2019 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 8, 2019 Post-IPO Equity $800M 1 Regeneron — Detail
Mar 28, 2011 Post-IPO Equity $10M 1 Takeda — Detail
Jul 7, 2003 Private Equity（PE） $24.60M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Alnylam Pharmaceuticals is funded by 4 investors. Regeneron and Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
Regeneron Yes Post-IPO Equity
Takeda Yes Post-IPO Equity
Merck — Private Equity（PE）
ARCH Venture Partners — Private Equity（PE）
Cointime
Содержание
компания